Gain Therapeutics (GANX) Debt to Equity (2019 - 2026)
Gain Therapeutics (GANX) debt to equity from Dec 31, 2019 to Mar 31, 2026. The current Gain Therapeutics (GANX) debt to equity is 2.64%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Gain Therapeutics (GANX)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 2.16% | -64.05% |
| 2024 | 5.99% | +32.30% |
| 2023 | 4.53% | +42.58% |
| 2022 | 3.18% | +60.37% |
| 2021 | 1.98% | -83.40% |
| 2020 | 11.94% | N/A |
| 2019 | 0.00% | N/A |
Comparison Gain Therapeutics (GANX) debt to equity with competitors
Gain Therapeutics (GANX) debt to equity is 2.64%.